NK Cell-Dependent Antibody-Mediated Immunotherapy Is Improved In Vitro and In Vivo When Combined with Agonists for Toll-like Receptor 2 in Head and Neck Cancer Models

The immunosuppressive character of head and neck cancers may explain the relatively low response rates to antibody therapy targeting a tumor antigen, such as cetuximab, and anti-PD-1 checkpoint inhibition. Immunostimulatory agents that overcome tumor-derived inhibitory signals could augment therapeu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of molecular sciences Jg. 22; H. 20; S. 11057
Hauptverfasser:	Gruijs, Mandy, Ganzevles, Sonja H., Stigter-van Walsum, Marijke, van der Mast, Richard, van Ostaijen-ten Dam, Monique M., Tuk, Cornelis W., Schilham, Marco W., Leemans, C. René, Brakenhoff, Ruud H., van Egmond, Marjolein, van de Ven, Rieneke, Bakema, Jantine E.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Switzerland MDPI AG 14.10.2021 MDPI
Schlagworte:	Agonists Animals Antibodies Antibody-Dependent Cell Cytotoxicity - immunology Binding sites Cancer Cell Line, Tumor Cetuximab - pharmacology Cetuximab - therapeutic use Chemotherapy Cytokines Cytokines - metabolism Cytotoxicity Drug Therapy, Combination Experiments FDA approval Female Growth factors Head & neck cancer Head and Neck Neoplasms - therapy Human papillomavirus Humans Immunotherapy Killer Cells, Natural - immunology Leukocytes, Mononuclear - cytology Leukocytes, Mononuclear - drug effects Leukocytes, Mononuclear - metabolism Ligands Lipopeptides - pharmacology Lipopeptides - therapeutic use Mice Mice, Nude Monoclonal antibodies Radiation therapy Receptors, IgG - agonists Receptors, IgG - metabolism Targeted cancer therapy Toll-Like Receptor 2 - agonists Toll-Like Receptor 2 - metabolism Transplantation, Heterologous NK cells antibody-dependent cellular cytotoxicity TLR agonists head and neck cancer immunotherapy cetuximab immunosuppression
ISSN:	1422-0067, 1661-6596, 1422-0067
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!